Clinical Trial Update: Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update reporting safety, hemodynamic effects, and pharmacokinetics of the investigational agent CXL-1020 in patients with stable heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• CXL-1020

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Heart Failure | Phase 1, Phase 2 | Status: COMPLETED